Summary
While radionuclide therapy has been effective using radiolabeled antibodies in the treatment of solid tumors in animal models and in the clinical treatment of diffuse (liquid) malignancies, similar successes are rarely seen in the treatment solid tumors in the clinical setting. Alternate strategies are needed to improve the clinical efficacy. There is an emerging body of evidence that this could be accomplished through a number of means including; the use of radiation sensitizers, the normalization of tumor vasculature, the selectively enhancement of tumor vascular permeability or the use of combination therapy with agents that have complementary therapeutic effects.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. NEJM, 354:567-578, 2006.
Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 62:4263-4272, 2002.
Cardillo TM, Blumenthal R, Ying Z, Gold DV. Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer. Int. J. Cancer 97:386-392, 2002.
C urran D, Giralt J, Harari PM, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J. Clin. Oncol. 25:2191-2197, 2007.
E llis LM. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin. Oncol. 33(5 Suppl 10):S1-7, 2006.
Fukutome M, Maebayashi K, Nasu S, Seki K, Mitsuhashi N. Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 (“Iressa”) and trastuzumab (“Herceptin”). Int. J. Radiat. Oncol. Biol. Phys. 66:528-536, 2006.
Gold DV, Schutsky K, Modrak D, Cardillo TM. Low-dose radioimmunotherapy (90Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. Clin. Cancer Res. 9(Suppl):3929s-3937s, September 1, 2003.
Kelly MP, Lee FT, Tahtis K, Smyth FE, Brechbiel MW, Scott AM. Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy. Clin. Cancer Res. 13:5604s-5612s, 2007.
K imura Y, Inoue K, Abe M, Nearman J, Baranowska-Kortylewicz J. PDGFRbeta and HIF1alpha inhibition with imatinib and radioimmunotherapy of experimental prostate cancer. Cancer Biol. Ther. 6(11):1763-1772, 2007 [Epub].
Kinuya S, Yokoyama K, Yamamoto W, et al. Short-period-induced hypertension could improve tumor-to-nontumor ratios of radiolabeled monoclonal antibody. Nucl. Med. Biol. 24:547-551, 1997.
Kinuya S, Yokoyama K, Kawashima A, et al. Pharmacologic intervention with angiotensin II and kininase inhibitor enhanced efficacy of radioimmunotherapy in human colon cancer xenografts. J. Nucl. Med. 41:1244-1249, 2000.
Kinuya S, Kawashima A, Yokoyama K, et al. Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts. J. Nucl. Med. 43:1084-1089, 2002.
Koppe MJ, Oyen WJ, Bleichrodt RP, Verhofstad AA, Goldenberg DM, Boerman OC. Combination therapy using gemcitabine and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin. Cancer Biother. Radiopharm. 21:506-514, 2006.
Kraeber-Bodéré F, Saï-Maurel C, Campion L, et al. Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Mol. Cancer Ther. 1:267-274, 2002.
Lawrence TS, Eisbruch, A, Shewach DS. Gemcitabine mediated radiosensitization. Semin. Oncol. 24: S7-24, 1997.
Lee FT, Mountain AJ, Kelly MP, et al. Enhanced efficacy of radioimmunotherapy with 90YCHX-A¢¢-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478. Clin Cancer Res. 11:7080s-7086s, 2005.
Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Mol. Cancer Ther. 2:1113-1120, 2003.
Macklis RM. Radioimmunotherapy as a therapeutic option for non-Hodgkin’s lymphoma. Semin. Radiat. Oncol. 17:176-183, 2007.
McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides. J. Nat. Cancer. Inst. (Bethesda) 88:1193-1203, 1996.
Milas L, Fang FM, Mason KA, et al. Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. Int. J. Radiat. Oncol. Biol. Phys. 67:568-572, 2007.
Milenic DE, Garmestani K, Brady ED, et al. Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease. Clin. Cancer Res. 13:1926-1935, 2007.
O’Donnell RT, DeNardo SJ, Miers LA, et al. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6. Prostate 50:27-37, 2002.
Oehler C, Dickinson DJ, Broggini-Tenzer A, et al. Current concepts for the combined treatment modality of ionizing radiation with anticancer agents. Curr. Pharm. Des. 13:519- 535, 2007.
Pedley RB, El-Emir E, Flynn AA, et al. Synergy between vascular targeting agents and antibody-directed therapy. Int. J. Radiat. Oncol. Biol. Phys. 54:1524-1531, 2002.
Pegram M, Chan D, Dichmann RA, et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. Breast Cancer Res. Treat. 100(Suppl 1):S28 (abstract 301).
Richman CM, Denardo SJ, O’Donnell RT, et al. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker wit cyclosporine to prevent human anti-mouse antibody. Clin. Cancer Res. 11:5920-5927, 2005.
Sartor, CG, Carey, L, Dees, EC, Ollila, D, Sherron, R, et al. Radiosensitization of locally advanced breast cancer with Herceptin - initial toxicity results of a phase II trial. In: San Antonio Breast Cancer Meeting, 2003.
Sato S, Kajiyama Y, Sugano M, et al. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophagealcancer cell lines expressing HER-2/neu oncoprotein. Int. J. Radiat. Oncol. Biol. Phys. 61:203-211, 2005.
Shewach DS, Hahn TM, Chang E., Hertel LW, Lawrence TS. Metabolism of 2_,2_-Difluoro2_-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res, 54:3218-3223, 1994.
Spalding AC, Lawrence TS. New and emerging radiosensitizers and radioprotectors. Cancer Invest 24:444-546, 2006.
Tong RT, Boucher Y, Kozin SV,Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64:3731-3736, 2004.
Winkler F, Kozin SV,Tong RT, et al. Kinetics of vascular normalization byVEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 6:553-563, 2004.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science + Business Media B.V
About this chapter
Cite this chapter
Adams, G.P. (2008). Enhancing the Efficiency of Targeted Radionuclide Therapy. In: Stigbrand, T., Carlsson, J., Adams, G.P. (eds) Targeted Radionuclide Tumor Therapy. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-8696-0_18
Download citation
DOI: https://doi.org/10.1007/978-1-4020-8696-0_18
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-8695-3
Online ISBN: 978-1-4020-8696-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)